Zai Lab (ZLAB) reported $460M in revenue for fiscal 2025, +15.3% year on year. That ranks #2265 by revenue among 2853 SEC filers and #221 in Healthcare. It posted a net loss of −$176M for the same year. Revenue has grown 221.7% a year on average since 2018 ($129,000 then). The fiscal 2025 balance sheet shows $1.2B in total assets and $680M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $460M | +15.3% | FY20252025-12-31 |
| Gross profitGrossProfit | $85,862 | — | FY20182018-12-31 |
| Operating incomeOperatingIncomeLoss | −$229M | +$52.7M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$176M | +$81.6M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$151M | +$64.1M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $8.1M | +43.2% | FY20252025-12-31 |
| Total assetsAssets | $1.2B | −1.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $716M | −14.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $680M | +51.1% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $99.6M | −$51.0M | Open → |
| Q2 20262026-06-30 | $106M | −$50.8M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Zai Lab Ltd
- Ticker
- ZLAB
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001704292
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Travere TherapeuticsTVTX | $491M | −$25.5M |
| Porch GroupPRCH | $482M | −$3.4M |
| Natures Sunshine ProductsNATR | $480M | $19.5M |
| Zai LabZLAB | $460M | −$176M |
| AccurayARAY | $459M | −$1.6M |
| Tarsus PharmaceuticalsTARS | $451M | −$66.0M |
| ArtivionAORT | $441M | $9.8M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Zai Lab — Key figures |url=https://companiesranked.com/en/company/zai-lab |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Zai Lab — Key figures. CompaniesRanked. https://companiesranked.com/en/company/zai-labBibTeX
@misc{companiesranked-en-company-zai-lab-2026,
author = {{CompaniesRanked}},
title = {{Zai Lab — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/zai-lab}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001704292-26-000015 · February 26, 2026
{{cite web |title=Zai Lab — Key figures — 10-K (0001704292-26-000015) |url=https://www.sec.gov/Archives/edgar/data/1704292/000170429226000015/zlab-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.